{"product_id":"global-brugada-syndrome-market-size-study-forecast-by-diagnosis-electrocardiogram-electrophysiology-test-genetic-testing-and-others-treatment-implantable-cardioverter-defibrillator-and-drug-therapy-and-end-user-hospitals-clinics-surgical","title":"Global Brugada Syndrome Market Size study \u0026 Forecast, by Diagnosis (Electrocardiogram, Electrophysiology Test, Genetic Testing, and Others), Treatment (Implantable Cardioverter-Defibrillator, and Drug Therapy), and End User (Hospitals \u0026 Clinics, Surgical","description":"\u003cp\u003eGlobal Brugada Syndrome Market Size study \u0026amp; Forecast, by Diagnosis (Electrocardiogram, Electrophysiology Test, Genetic Testing, and Others), Treatment (Implantable Cardioverter-Defibrillator, and Drug Therapy), and End User (Hospitals \u0026amp; Clinics, Surgical Centers, Diagnostic Centers, and Others) and Regional Analysis, 2022-2029\u003c\/p\u003e\n\n\u003cp\u003eGlobal Brugada Syndrome Market is valued at approximately USD 1.32 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.5% over the forecast period 2022-2029. Brugada Syndrome is a rare genetic disorder that affects the way electrical signals pass through the heart. It is an autosomal dominant genetic disorder and can be inherited from just one parent. Brugada Syndrome causes disruptions to the normal rhythm of the heart. Signs and symptoms associated with Brugada Syndrome include dizziness. fainting. gasping and laboured breathing, irregular heartbeats, or palpitations as well as extremely fast and chaotic heartbeat among others. The increasing incidence of heart-related diseases and growing prevalence of Brugada Syndrome as well as strategic initiatives from leading market players are key factors accelerating the market growth.\u003c\/p\u003e\n\n\u003cp\u003eAccording to the World Health Organization (WHO)’s estimates – as of 2019, globally around 17.9 million people lost their lives due to CVDs, witnessing for over 32% of all global deaths. In addition, around 85% CVD related deaths are caused by heart attack stroke. Moreover, as per The National Organization for Rare Disorders – in 2019, the prevalence of Brugada Syndrome in the United States was estimated at 5 in 10,000 people. Also, rising awareness of genetic syndromes and growing pharmaceuticals \u0026amp; biotechnology industry would create lucrative growth prospects for the market over the forecast period. However, the high treatment cost associated with Brugada Syndrome stifles market growth throughout the forecast period of 2022-2029.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Brugada Syndrome Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factors such as the presence of key market players as well as availability of well-established healthcare infrastructure in the region. Whereas the Asia Pacific is expected to grow with the highest CAGRduring the forecast period, owing to factors such as the rising prevalence of Brugada Syndrome as well as growing healthcare infrastructure in the region.\u003c\/p\u003e\n\n\u003cp\u003eMajor market player included in this report are:\u003cbr\u003e\nNovartis AG\u003cbr\u003e\nF. Hoffmann-La Roche Ltd\u003cbr\u003e\nBoehringer Ingelheim International GmbH.\u003cbr\u003e\nPfizer Inc.\u003cbr\u003e\n Ionis Pharmaceuticals Inc.\u003cbr\u003e\n Abbott\u003cbr\u003e\n Novo Nordisk A\/S\u003cbr\u003e\n Takeda Pharmaceutical Company Limited.\u003cbr\u003e\n AstraZeneca\u003cbr\u003e\n Cytokinetics, Inc.\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\nIn October 2020, USA-based Abbott Laboratories launched new Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronisation Therapy Defibrillator (CRT-D) devices. These new devices are intended for the patient suffering from abnormal heart rhythms and heart failure.\u003c\/p\u003e\n\n\u003cp\u003eIn December 2021, Massachusetts, USA-based Boston Scientific announced a clinical trial of its first modular cardiac rhythm implant system. This new system is comprised of a leadless pacemaker and an implantable cardioverter defibrillator. This new system aimed at controlling the abnormal beating of the heart.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Brugada Syndrome Market Report Scope:\u003cbr\u003e\nHistorical Data 2019-2020-2021\u003cbr\u003e\nBase Year for Estimation 2021\u003cbr\u003e\nForecast period 2022-2029\u003cbr\u003e\nReport Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered\u003c\/p\u003e\n\n \u003cp\u003eDiagnosis, Treatment, End User, Region\u003cbr\u003e\nRegional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World\u003cbr\u003e\nCustomization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional \u0026amp; segment scope*\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:\u003cbr\u003e\nBy Diagnosis\u003cbr\u003e\nElectrocardiogram\u003cbr\u003e\nElectrophysiology Test\u003cbr\u003e\nGenetic Testing\u003cbr\u003e\nOthers\u003cbr\u003e\nBy Treatment\u003cbr\u003e\nImplantable Cardioverter-Defibrillator\u003cbr\u003e\nDrug Therapy\u003cbr\u003e\nBy End User\u003cbr\u003e\nHospitals \u0026amp; Clinics\u003cbr\u003e\nSurgical Centers\u003cbr\u003e\nDiagnostic Centers\u003cbr\u003e\nOthers\u003cbr\u003e\nBy Region:\u003cbr\u003e\nNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nRest of the WorldCompanies Mentioned\u003c\/p\u003e\n\n\u003cp\u003eNovartis AG\u003cbr\u003e\nF. Hoffmann-La Roche Ltd\u003cbr\u003e\nBoehringer Ingelheim International GmbH.\u003cbr\u003e\nPfizer Inc.\u003cbr\u003e\nIonis Pharmaceuticals Inc. \u003cbr\u003e\nAbbott\u003cbr\u003e\nNovo Nordisk A\/S\u003cbr\u003e\nTakeda Pharmaceutical Company Limited.\u003cbr\u003e\nAstraZeneca\u003cbr\u003e\nCytokinetics, Inc.\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 200 Pages \/ MCW16238846","offer_id":47653804507442,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-brugada-syndrome-market-size-study-forecast-by-diagnosis-electrocardiogram-electrophysiology-test-genetic-testing-and-others-treatment-implantable-cardioverter-defibrillator-and-drug-therapy-and-end-user-hospitals-clinics-surgical","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}